Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 1992 March; 89(3): 774–781.
PMCID: PMC442921

Targeted enhancement of the biological activity of the antineoplastic agent, neocarzinostatin. Studies in murine neuroblastoma cells.


The development of chemotherapeutic approaches to cancer has been hampered by the toxicity of proposed agents for normal rapidly dividing cells. By using neocarzinostatin, a "pro-drug" which is activated by reduction by thiol compounds, adjunctively with 6-mercaptodopamine, a thiol-containing dopamine analogue, we have been able to enhance neocarzinostatin toxicity for cells of the neural crest tumor neuroblastoma. Thiol compounds that are not neurotransmitter analogues do not act synergistically with neocarzinostatin in this system. Since most normal rapidly dividing cells do not have surface dopamine receptors, we propose this approach for the selective targeting of toxicity for neuroblastoma cells. We further introduce cell-selective activation of prodrugs as a new chemotherapeutic strategy which demands further development.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Napier MA, Holmquist B, Strydom DJ, Goldberg IH. Neocarzinostatin: spectral characterization and separation of a non-protein chromophore. Biochem Biophys Res Commun. 1979 Jul 27;89(2):635–642. [PubMed]
  • Schor NF. Neocarzinostatin induces neuronal morphology of mouse neuroblastoma in culture. J Pharmacol Exp Ther. 1989 Jun;249(3):906–910. [PubMed]
  • Kappen LS, Napier MA, Goldberg IH. Roles of chromophore and apo-protein in neocarzinostatin action. Proc Natl Acad Sci U S A. 1980 Apr;77(4):1970–1974. [PubMed]
  • DeGraff WG, Mitchell JB. Glutathione dependence of neocarzinostatin cytotoxicity and mutagenicity in Chinese hamster V-79 cells. Cancer Res. 1985 Oct;45(10):4760–4762. [PubMed]
  • Chavdarian CG, Castagnoli N., Jr Synthesis, redox characteristics, and in vitro norepinephrine uptake inhibiting properties of 2-(2-mercapto-4,5-dihydroxyphenyl)ethylamine (6-mercaptodopamine). J Med Chem. 1979 Nov;22(11):1317–1322. [PubMed]
  • ELLMAN GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959 May;82(1):70–77. [PubMed]
  • Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969 Mar;27(3):502–522. [PubMed]
  • Kappen LS, Goldberg IH. Activation and inactivation of neocarzinostatin-induced cleavage of DNA. Nucleic Acids Res. 1978 Aug;5(8):2959–2967. [PMC free article] [PubMed]
  • Seelig GF, Meister A. Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney. Methods Enzymol. 1985;113:379–390. [PubMed]
  • Natale RB, Yagoda A, Watson RC, Stover DE. Phase II trial of neocarzinostatin in patients with bladder and prostatic cancer: toxicity of a five-day iv bolus schedule. Cancer. 1980 Jun 1;45(11):2836–2842. [PubMed]
  • Satake I, Tari K, Yamamoto M, Nishimura H. Neocarzinostatin-induced complete regression of metastatic renal cell carcinoma. J Urol. 1985 Jan;133(1):87–89. [PubMed]
  • McKelvey EM, Murphy W, Zander A, Bodey GP. Neocarzinostatin: report of a phase II clinical trial. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):699–701. [PubMed]
  • Maeda H, Ueda M, Morinaga T, Matsumoto T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J Med Chem. 1985 Apr;28(4):455–461. [PubMed]
  • Oka K, Miyamoto Y, Matsumura Y, Tanaka S, Oda T, Suzuki F, Maeda H. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation. Pharm Res. 1990 Aug;7(8):852–855. [PubMed]
  • Cornaglia-Ferraris P, Ponzoni M, Montaldo P, Mariottini GL, Donti E, Di Martino D, Tonini GP. A new human highly tumorigenic neuroblastoma cell line with undetectable expression of N-myc. Pediatr Res. 1990 Jan;27(1):1–6. [PubMed]
  • Prasad KN, Kumar S. Role of cyclic AMP in differentiation of human neuroblastoma cells in culture. Cancer. 1975 Oct;36(4):1338–1343. [PubMed]
  • Seeger RC, Siegel SE, Sidell N. Neuroblastoma: clinical perspectives, monoclonal antibodies, and retinoic acid. Ann Intern Med. 1982 Dec;97(6):873–884. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation